Your browser does not support JavaScript! MONISTAT-DERM (MICONAZOLE NITRATE) CREAM [ORTHO DERMATOLOGICAL]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

monistat-derm (Miconazole nitratecream 
[Ortho Dermatological]

Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL
Drug Label Sections

For Topical Use Only

Description:

MONISTAT-DERM (miconazole nitrate 2%) Cream contains miconazole nitrate* 2%, formulated into a water-miscible base consisting of pegoxol 7 stearate, peglicol 5 oleate, mineral oil, benzoic acid, butylated hydroxyanisole and purified water.

*Chemical name: 1-[2,4-dicholoro-B-{(2,5-dichlorobenzyl) oxy} phenethyl] imidazole mononitrate.

Actions:

Miconazole nitrate is a synthetic antifungal agent which inhibits the growth of the common dermatophytes, Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, the yeast-like fungus, Candida albicans, and the organism responsible for tinea versicolor (Malassezia furfur).

Indications:

For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.

Contraindications:

MONISTAT-DERM (miconazole nitrate 2%) Cream has no known contraindications.

Precautions:

If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued.

For external use only. Avoid introduction of MONISTAT-DERM Cream into the eyes.

Adverse Reactions:

There have been isolated reports of irritation, burning, maceration, and allergic contact dermatitis associated with the application of MONISTAT-DERM.

Dosage and Administration:

Sufficient MONISTAT-DERM Cream should be applied to cover affected areas twice daily (morning and evening) in patients with tinea pedis, tinea cruris, tinea corporis, and cutaneous candidiasis, and once daily in patients with tinea versicolor. If MONISTAT-DERM Cream is used in intertriginous areas, it should be applied sparingly and smoothed in well to avoid maceration effects.

Early relief of symptoms (2 to 3 days) is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, Candida infections and tinea cruris and corporis should be treated for two weeks and tinea pedis for one month in order to reduce the possibility of recurrence. If a patient shows no clinical improvement after a month of treatment, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

How Supplied:

MONISTAT-DERM (miconazole nitrate 2%) Cream containing miconazole nitrate at 2% strength is supplied in 15g, 1 oz. and 3 oz. tubes.

Ortho Dermatological
Division of Ortho-McNeil
Pharmaceutical, Inc.
Skillman, New Jersey 08558

© OMP 2001
Printed in U.S.A.
Revised February 2001
631-10-471-3

MONISTAT-DERM 
miconazole nitrate cream
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:0062-5434
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Miconazole nitrate (Miconazole nitrate) 20 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
Pegoxol 7 stearate 
Peglicol 5 oleate 
Mineral oil 
Benzioc acid 
Butylated hydroxyanisole 
Water 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0062-5434-0215 g in 1 TUBE
2NDC:0062-5434-0128 g in 1 TUBE
3NDC:0062-5434-0385 g in 1 TUBE
Labeler - Ortho Dermatological

Revised: 4/2007
 
Ortho Dermatological

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services